Pharmaceutical giant Eli Lilly to invest $27 billion in US manufacturing expansion

The investment marks a significant expansion amid rising demand for weight loss and diabetes medications. The move also coincides with President Donald Trump’s push to increase domestic manufacturing and reduce reliance on foreign supply chains. Trump has pressured pharmaceutical companies to invest in US production, warning of potential tariffs for those that manufacture abroad.

The company revealed its plans at an event in Washington, DC, attended by Trump administration officials, including Kevin Hassett, director of the White House National Economic Council, and Commerce Secretary Howard Lutnick. According to CNBC, Lutnick credited the Trump administration for the decision, saying the investment is “exactly what the Trump administration is all about, which is building and manufacturing and reshoring in America, investing in America, building in America.” He thanked Eli Lilly for “doing exactly what the president was hoping would happen.”

With this latest commitment, Eli Lilly’s total US manufacturing investments have exceeded $50 billion in recent years. Since 2020, the company has already spent $23 billion on new facilities to address supply shortages of high-demand drugs.

“This represents the largest pharmaceutical expansion investment in US history,” said CEO David Ricks. “We’re making these investments ... to prepare for the demand we anticipate for future pipeline medicines across our therapeutic areas.”

While Eli Lilly is working to develop drugs for conditions such as cancer and Alzheimer’s, its obesity and diabetes medications have drawn significant attention in recent years. The success of Zepbound and Mounjaro comes amid a growing market for GLP-1 drugs, including Novo Nordisk’s popular drugs Wegovy and Ozempic.